Table 3 Haematological toxicity in high and standard cytogenetic risk relapsed/refractory multiple myeloma (pooled results of the POLLUX and the CASTOR studies).
Daratumumab-containing treatment (n/N, %) | Control treatment (n/N, %) | |
|---|---|---|
All grade anaemia | ||
Standard cytogenetic risk MM | 116/329 (35.3%) | 103/312 (33%) |
High cytogenetic risk MM | 20/75 (26.7%) | 29/68 (42.6%) |
Grade 3–4 anaemia | ||
Standard cytogenetic risk MM | 56/329 (17%) | 55/312 (17.6%) |
High cytogenetic risk MM | 11/75 (14.7) | 16/68 (23.5%) |
All grade lymphopenia | ||
Standard cytogenetic risk MM | 28/329 (8.5%) | 25/312 (8%) |
High cytogenetic risk MM | 9/75 (12%) | 7/68 (10.3%) |
Grade 3–4 lymphopenia | ||
Standard cytogenetic risk MM | 22/329 (6.7%) | 10/312 (3.2%) |
High cytogenetic risk MM | 8/75 (10.7%) | 6/68 (8.8%) |
All grade neutropenia | ||
Standard cytogenetic risk MM | 145/329 (44.1%) | 96/312 (30.8%) |
High cytogenetic risk MM | 31/75 (41.3%) | 21/68 (30.9%) |
Grade 3–4 neutropenia | ||
Standard cytogenetic risk MM | 124/329 (37.7%) | 75/312 (24.0%) |
High cytogenetic risk MM | 23/75 (30.7%) | 18/68 (26.5%) |
All grade thrombocytopenia | ||
Standard cytogenetic risk MM | 140/329 (42.6%) | 104/312 (33.3%) |
High cytogenetic risk MM | 37/75 (49.3%) | 30/68 (44.1%) |
Grade 3–4 thrombocytopenia | ||
Standard cytogenetic risk MM | 90/329 (27.4%) | 69/312 (22.1%) |
High cytogenetic risk MM | 27/75 (36%) | 22/68 (32.4%) |
